Medicine and Dentistry
Amino Terminal Sequence
7%
Anthracycline
9%
Biological Marker
21%
Bleomycin
11%
Blood Vessel Injury
8%
Breast Cancer
37%
Cancer
9%
Cancer Therapy
23%
Cardiotoxicity
12%
Cardiovascular Disease
26%
Cardiovascular Risk
19%
Cardiovascular System
25%
Childhood Cancer
9%
Cisplatin
45%
Combination Chemotherapy
7%
Diagnosis
7%
Disease
29%
Gamma Urogastrone
7%
Gastrointestinal Stromal Tumor
10%
Germ Cell Cancer
18%
Germinoma
27%
Hazard Ratio
10%
Heart Failure
9%
Heart Function
12%
Homologous Recombination
7%
Kidney Function
9%
Late Effect
9%
Malignant Neoplasm
60%
Metabolic Syndrome
19%
Neoplasm
50%
Non Seminomatous Germinoma
7%
Oncology
14%
Orchiectomy
7%
Ovarian Cancer
23%
Overall Survival
14%
Pharmacokinetics
8%
Plasminogen Activator Inhibitor-1
7%
Population
7%
Positron Emission Tomography
20%
Positron Emission Tomography
18%
Prevalence
11%
Programmed Cell Death
13%
Progression Free Survival
11%
Quality of Life
8%
Radiation Therapy
30%
Radioactive Tracer
15%
Surgery
9%
Testis Cancer
100%
Transitional Cell Carcinoma
7%
Zirconium 89
12%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
7%
Angiogenesis Inhibitor
10%
Anthracycline
19%
Anticarcinogen
6%
Bevacizumab
7%
Biological Marker
19%
Bleomycin
21%
Brain Natriuretic Peptide
11%
Breast Cancer
34%
Carboplatin
11%
Cardiotoxicity
23%
Cardiovascular Disease
15%
Cardiovascular Risk
15%
Chemotherapy
93%
Cisplatin
59%
Diarrhea
6%
Disease
27%
Epidermal Growth Factor Receptor 2
10%
Etoposide
6%
Fluorouracil
6%
Gamma Urogastrone
8%
Gastrointestinal Stromal Tumor
13%
Gemcitabine
10%
Germ Cell Cancer
17%
Germ Cell Tumor
7%
Heart Failure
15%
Imatinib
9%
Inflammation
7%
Lobaplatin
7%
Lung Toxicity
8%
Malignant Neoplasm
55%
Maximum Tolerated Dose
7%
Metabolic Syndrome X
7%
Neoplasm
46%
Non Seminomatous Germinoma
7%
Ovary Cancer
16%
Overall Survival
16%
Paclitaxel
8%
Pharmacodynamics
7%
Pharmacokinetics
31%
Prevalence
7%
Progression Free Survival
12%
Protein P53
9%
Second Cancer
6%
Solid Malignant Neoplasm
18%
Testis Cancer
81%
Thrombospondin 1
7%
Tracer
10%
Trastuzumab
14%
Zirconium 89
9%
Keyphrases
5-fluorouracil (5-FU)
5%
Advanced Ovarian Cancer
7%
Angiogenesis Inhibitors
5%
Antibody Uptake
5%
Cancer Patients
16%
Cancer Treatment
17%
Carboplatin
6%
Cardiac Function
5%
Cardiac Substructures
5%
Cardiovascular Disease
8%
Cardiovascular Events
5%
Cardiovascular Morbidity
10%
Cardiovascular Risk
11%
Chemotherapy
23%
Cisplatin
12%
Cisplatin-based Chemotherapy
14%
Collaborative Groups
5%
Confidence Interval
5%
Exercise Intervention
5%
Gemcitabine Plus Cisplatin
5%
Germ Cell Tumor
9%
Hazard Ratio
7%
High Risk
5%
In Cancer
6%
Late Effects
7%
Long-term Breast Cancer Survivors
5%
Long-term Survivors
5%
Maximum Tolerated Dose
5%
Metabolic Syndrome
8%
Metachronous
5%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
5%
Non-seminomatous Germ Cell Tumor (NSGCT)
5%
Pharmacokinetics
9%
Phase I Study
13%
Platinum-based Chemotherapy
5%
Radiotherapy
8%
Solid Tumors
5%
Testicular Cancer
43%
Testicular Cancer Survivors
14%
Testicular Germ Cell Tumor
7%
Thrombospondin-1 (TSP-1)
5%
Vascular Toxicity
5%
Zr-89
5%
